Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial

The Lancet

Volumn 373, Issue 9659, 2009, Pages 215-225

  van Marrewijk, Corine J ^a   Mujakovic, Suhreta ^b   Fransen, Gerdine AJ ^c   Numans, Mattijs E ^b   de Wit, Niek J ^b   Muris, Jean WM ^c   van Oijen, Martijn GH ^a   Jansen, Jan BMJ ^a   Grobbee, Diederik E ^b   Knottnerus, J André ^c   Laheij, Robert JF ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPEPSIA; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SYMPTOM; TASTE AVERSION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 58149463210     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60070-2     Document Type: Article

References (40)

1. Anon. Management of dyspepsia: report of a working party. Lancet 1 (1988) 576-579
2. Heading R.C. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 231 (1999) 3-8
3. Health Council of the Netherlands (GR). Management of dyspepsia. Report No 2000/26 (2000), Health Council of the Netherlands, The Hague
4. Laheij R.J., and Severens J.L. Cost of endoscopy in economic evaluation. Gastroenterology 113 (1997) 2023-2024
5. Delaney B.C., Ford A.C., Forman D., Moayyedi P., and Qume M. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 4 (2005) CD001961.
6. Talley N.J., and Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 100 (2005) 2324-2337
7. Chey W.D., and Moayyedi P. Review article: uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther 19 suppl 1 (2004) 1-8
8. In: Drossman D.A., Corazziari E., Talley N.J., Thompson W.G., and Whitehead W.E. (Eds). Rome II: the functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment: a multinaltional consensus. 2 edn. (2000), Degnon Associates, McLean, VA, USA
9. Makris N., Barkun A., Crott R., and Fallone C.A. Cost-effectiveness of alternative approaches in the management of dyspepsia. Int J Technol Assess Health Care 19 (2003) 446-464
10. Talley N.J. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 129 (2005) 1753-1755
11. van Zanten S.V., Bradette M., Chiba N., et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 19 (2005) 285-303
12. National Institute for Clinical Excellence (NICE). Dyspepsia: management of dyspepsia in adults in primary care. Clinical guideline 17 (2004), National Institute for Clinical Excellence, London
13. Scottish Intercollegiate Guidelines Network. Dyspepsia: a national clinical guideline. Report no 68 (2003), Scottish Intercollegiate Guidelines Network, Edinburgh
14. Dutch Institute for Healthcare Improvement (CBO), Dutch College of General Practitioners (NHG). Multidisciplinary guideline "dyspepsia" (2004), Dutch Institute for Healthcare Improvement and Dutch College of General Practitioners, Alphen aan den Rijn, Netherlands (in Dutch).
15. Fransen G.A., van Marrewijk C.J., Mujakovic S., et al. Pragmatic trials in primary care. Methodological challenges and solutions demonstrated by the DIAMOND-study. BMC Med Res Methodol 7 (2007) 16
16. Heading R.C. Definitions of dyspepsia. Scand J Gastroenterol Suppl 182 (1991) 1-6
17. Straus W.L., Ofman J.J., MacLean C., et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 97 (2002) 1951-1958
18. Bovenschen H.J., Janssen M.J., van Oijen M.G., Laheij R.J., van Rossum L.G., and Jansen J.B. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci 51 (2006) 1509-1515
19. Brooks R. EuroQol: the current state of play. Health Policy 37 (1996) 53-72
20. Lamers L.M., Stalmeier P.F., McDonnell J., Krabbe P.F., and van Busschbach J.J. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd 149 (2005) 1574-1578 (in Dutch).
21. Oostenbrink J.B., Bouwmans C.A., Koopmanschap M.A., and Rutten F.F. Guidelines for economic research: methods and standard costprices for health-economic evaluations (2004), Board of Health Insurances, Diemen, Netherlands (in Dutch).
22. Board of Health Insurances (CVZ). Pharmacotherapeutic precept (2006), Board of Health Insurances, Diemen. http://www.fk.cvz.nl (accessed February 2007; in Dutch).
23. Board of Health Insurances (CVZ). Medication costs (2006), Board of Health Insurances, Diemen. http://www.medicijnkosten.nl (accessed February 2007).
24. Goves J., Oldring J.K., Kerr D., et al. First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther 12 (1998) 147-157
25. Meineche-Schmidt V., and Christensen E. Which dyspepsia patients will benefit from omeprazole treatment? Analysis of a Danish multicenter trial. Am J Gastroenterol 95 (2000) 2777-2783
26. 2-RA-start" management strategies in primary care-the CADET-HR Study. Aliment Pharmacol Ther 21 (2005) 1189-1202
27. Mason I., Millar L.J., Sheikh R.R., et al. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. Aliment Pharmacol Ther 12 (1998) 263-271
28. Howden C.W., Henning J.M., Huang B., Lukasik N., and Freston J.W. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 96 (2001) 1704-1710
29. Inadomi J.M., McIntyre L., Bernard L., and Fendrick A.M. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 98 (2003) 1940-1944
30. Festen H.P., Schenk E., Tan G., Snel P., and Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol 94 (1999) 931-936
31. Beck I.T. In support of "step-up therapy" for gastroesophageal reflux disease. Am J Gastroenterol 97 (2002) 503-504
32. Jones R., and Bytzer P. Review article: acid suppression in the management of gastro-oesophageal reflux disease-an appraisal of treatment options in primary care. Aliment Pharmacol Ther 15 (2001) 765-772
33. Talley N.J., Meineche-Schmidt V., Pare P., et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 12 (1998) 1055-1065
34. van Zanten S.V., Chiba N., Armstrong D., et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 100 (2005) 1477-1488
35. Laheij R.J., De Koning R.W., Horrevorts A.M., et al. Predominant symptom behavior in patients with persistent dyspepsia during treatment. J Clin Gastroenterol 38 (2004) 490-495
36. Grainger S.L., Klass H.J., Rake M.O., and Williams J.G. Prevalence of dyspepsia: the epidemiology of overlapping symptoms. Postgrad Med J 70 (1994) 154-161
37. Westbrook J.I., McIntosh J.H., and Talley N.J. The impact of dyspepsia definition on prevalence estimates: considerations for future researchers. Scand J Gastroenterol 35 (2000) 227-233
38. Panter S.J., O'Flanagan H., Bramble M.G., and Hungin A.P. Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome. Aliment Pharmacol Ther 19 (2004) 981-988
39. Holdstock G., and Bruce S. Endoscopy and gastric cancer. Gut 22 (1981) 673-676
40. Delaney B.C., Qume M., Moayyedi P., et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 336 (2008) 651-654